Blinatumomab
Pancytopenia Due To IKZF1 Mutations
Explore 4 assets in Pancytopenia Due To IKZF1 Mutations →Floatz Rating
CCC53/100
Confidence
Indicative
Sponsor
Nanfang Hospital, Southern Medical University
Modality
monoclonal_antibody
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
38Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06220487CT.gov A Single-arm, Open-label Study of Olverembatinib, CD3/CD19 Bispecific T-cell Engager, and Chidamide in Patients With Newly Diagnosed Ph+ALL | — | Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Pancytopenia Due To IKZF1 Mutations
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Blinatumomab (this asset) | Nanfang Hospital, Southern Medical University | P2 | CCC · 53 |
| Olverembatinib | Nanfang Hospital, Southern Medical University | P2 | CCC |
| Tucidinostat | Nanfang Hospital, Southern Medical University | P2 | CCC |
| Prednisone | Nanfang Hospital, Southern Medical University | P2 | CCC |
Other indications for Blinatumomab
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Precursor B-Cell Acute Lymphoblastic Leukemia | — | P3 | BBB · 72 |
| B-Lymphoblastic Leukemia/Lymphoma With T(9;22)(Q34.1;Q11.2) | — | P3 | BBB · 72 |
| Childhood Acute Lymphoblastic Leukemia | — | P3 | BB · 67 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Blinatumomab in Pancytopenia Due To IKZF1 Mutations. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/blinatumomab-pancytopenia-due-to-ikzf1-mutations
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →